Advertisement

Process Qualification: Stage 2 of the FDA Process Validation Guidance

  • Richard K. Burdick
  • David J. LeBlond
  • Lori B. Pfahler
  • Jorge Quiroz
  • Leslie Sidor
  • Kimberly Vukovinsky
  • Lanju Zhang
Chapter
Part of the Statistics for Biology and Health book series (SBH)

Abstract

In Chap. 3, the first stage of the FDA’s 2011 process validation guidance was described demonstrating various options to drive process understanding using experimental design . The resulting process design experiments yield information that can be used to define future operating ranges for the new process. The second stage of process validation is process qualification.

Keywords

Data analysis Effects of scale Equivalence testing Inter-batch variation Intra-batch variation Lot homogeneity Lot-to-lot variation Process characterization Process performance qualification (PPQ) Profiler PPQ batch size Risk management solution 

References

  1. ASTM E2475 (2010) Standard guide for process understanding related to pharmaceutical manufacture and control. ASTM International, West ConshohockenGoogle Scholar
  2. Breen C, Somayajula D A, Altekar M, Patel P, Lewis R (2016) Determining the number of process performance qualification batches using statistical tools—supplement to prior discussion paperGoogle Scholar
  3. Bryder M, Etling H, Flemming J, Hu Y, Levy P (2012, updated 2014) Topic 1—stage 2 process validation: determining and justifying the number of process performance qualification batches (Version 2). ISPE discussion paper. (www.ispe.org/discussion-papers/stage-2-process-validation.pdf)Google Scholar
  4. Chao S-B (2005) Risk-based approach for biological process validation: Integrating process validation with product development. J Validation Technol 12(1):54–68Google Scholar
  5. Doymaz F, Ye F, Burdick R (2015) Product homogeneity assessment during validation of biopharmaceutical drug product manufacturing processes. In: Jameel F, Hershenson S, MA K, Martin-Moe S (eds) Appears in quality by design for biopharmaceutical drug product development. Springer Science & Business Media, LLC, New York, pp 649–659Google Scholar
  6. European Medicines Agency (EMA) (2014) Guideline on process validation for finished products—information and data to be provided in regulatory submissionsGoogle Scholar
  7. International Conference on Harmonization (2000) Q7 good manufacturing practice guide for active pharmaceutical ingredientsGoogle Scholar
  8. International Conference on Harmonization (2005) Q9 quality risk managementGoogle Scholar
  9. Levy P (2012) Determining and justifying the number of process validation batches: making initial batch release decisions. ISPE: Lessons from 483s Process Validation TrackGoogle Scholar
  10. O’Donnell K, Greene A (2006a) A risk management solution designed to facilitate risk-based qualification, validation, and change control activities within GMP and pharmaceutical regulatory compliance environments in the EU: part I fundamental principles, design criteria, outline of process. J GXP Compliance 10(4):12–25Google Scholar
  11. O’Donnell K, Greene A (2006b) A risk management solution designed to facilitate risk-based qualification, validation, and change control activities within GMP and pharmaceutical regulatory compliance environments in the EU: part II tool scope, structure, limitations, principle findings, and novel elements. J GXP Compliance 10(4):26–35Google Scholar
  12. Parenteral Drug Association (PDA) (1998) Technical Report No. 29: Points to consider for cleaning validationGoogle Scholar
  13. Sidor L (2013) PPQ lot tool: determining the number of lots in PPQ. Validation Information Group, PDA Annual Meeting (April)Google Scholar
  14. Sidor L (2014) How many batches for PPQ? AAPS National Biotechnology Conference Short Course (May)Google Scholar
  15. Sidor L, Lewus P (2007) Validation and compliance: using risk analysis in process validation. BioPharm Int 20(2). http://www.biopharminternational.com/validation-compliance-using-risk-analysis-process-validation?id=&sk=&date=&%0A%09%09%09&pageID=2
  16. Strickland H, Altan S (2016) Process validation in the twenty-first century. In: Zhang L (ed) Chapter 19 of nonclinical statistics for pharmaceutical and biotechnology industries. Springer, Heidelberg, pp 501–531CrossRefGoogle Scholar
  17. Yang H (2013) How many batches are needed for process validation under the new FDA guidance? PDA J Pharm Sci Technol 67:53–62Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Richard K. Burdick
    • 1
  • David J. LeBlond
    • 2
  • Lori B. Pfahler
    • 3
  • Jorge Quiroz
    • 4
  • Leslie Sidor
    • 5
  • Kimberly Vukovinsky
    • 6
  • Lanju Zhang
    • 7
  1. 1.Elion LabsLouisvilleUSA
  2. 2.CMC StatisticsWadsworthUSA
  3. 3.Merck & Co., Inc.TelfordUSA
  4. 4.Merck & Co., Inc.KenilworthUSA
  5. 5.BiogenCambridgeUSA
  6. 6.PfizerOld SaybrookUSA
  7. 7.Nonclinical Statistics, Abbvie Inc.North ChicagoUSA

Personalised recommendations